Ipamorelin is a synthetic peptide investigated as a growth hormone secretagogue. It acts in the ghrelin-receptor system rather than being growth hormone itself. Its ability to influence hormone release is a pharmacological property, not proof of a general health benefit.

Where the selectivity description comes from

An early pharmacology paper described ipamorelin as a selective GH secretagogue based on the responses examined in experimental models. That finding is useful for understanding its development, but “selective” must remain tied to the tested systems and endpoints. It does not mean that a compound has no other effects or no risk. Raun and colleagues, 1998

A mechanism is not an outcome

A change in GH release does not establish improved strength, recovery, fat loss or longevity. Those claims require clinical studies designed to measure them. Results in animals, isolated cells or a different disease setting cannot be transferred automatically to healthy adults.

The exact formulation and route also matter. A study of one exposure does not validate every product sold under the same name.

Why safety language must be specific

FDA has described concerns about ipamorelin-related impurities, aggregation and immunogenicity, along with gaps in safety information for some routes. Its discussion also refers to serious events in an intravenous gastric-motility study. An event occurring during a study does not by itself establish causation, but it does prevent a simplistic “no known risk” conclusion. FDA safety-risk information

A responsible interpretation

Ipamorelin is a compound with an identifiable research mechanism and unresolved clinical questions. “Stimulates the body’s own hormone” is not a substitute for evidence of benefit and safety. This article explains the research category and does not recommend personal use.